Fruth Investment Management Cuts Position in Johnson & Johnson (JNJ)
Fruth Investment Management lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,314 shares of the company’s stock after selling 600 shares during the period. Johnson & Johnson makes up approximately 2.0% of Fruth Investment Management’s holdings, making the stock its 7th largest position. Fruth Investment Management’s holdings in Johnson & Johnson were worth $4,274,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Lenox Wealth Advisors Inc. increased its stake in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $117,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $186,000. Finally, Taylor Wealth Management Partners increased its stake in Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the period. 66.06% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.7369% on Friday, hitting $134.0708. The stock had a trading volume of 2,026,713 shares. The firm has a 50 day moving average price of $133.18 and a 200-day moving average price of $126.16. The company has a market cap of $359.85 billion, a price-to-earnings ratio of 22.6854 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.74 earnings per share. Analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
TRADEMARK VIOLATION NOTICE: “Fruth Investment Management Cuts Position in Johnson & Johnson (JNJ)” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/11/fruth-investment-management-cuts-position-in-johnson-johnson-jnj.html.
A number of equities analysts have weighed in on JNJ shares. UBS AG restated a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a report on Thursday, May 18th. Stifel Nicolaus restated a “hold” rating and issued a $128.00 price target (up previously from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Finally, Wells Fargo & Company restated a “market perform” rating and issued a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $133.72.
In related news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.